a public good project by the
Synthesis
Company
of California

© 2026

Alexandros Ardavanis | doi.page

0 works0 citations0 h-index

Alexandros Ardavanis

St Savas Hospital(GR)Anticancer Fund(BE)

Publications by Year

Research Areas

Cancer Treatment and Pharmacology, HER2/EGFR in Cancer Research, Immunotherapy and Immune Responses, Cancer Immunotherapy and Biomarkers, Colorectal Cancer Treatments and Studies

Most-Cited Works

→ A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer(2010)275 cited
→ Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients(2001)259 cited
→ The Role of BCL2 Family of Apoptosis Regulator Proteins in Acute and Chronic Leukemias(2011)254 cited
→ Breakthrough Cancer Pain: An Observational Study of 1000 European Oncology Patients(2013)192 cited
→ Vinorelbine Plus Cisplatin Versus Docetaxel Plus Gemcitabine in Advanced Non-Small-Cell Lung Cancer: A Phase III Randomized Trial(2005)163 cited
→ The prognostic significance of peritumoral tertiary lymphoid structures in breast cancer(2019)151 cited

→ Docetaxel Versus Docetaxel Plus Cisplatin As Front-Line Treatment of Patients With Advanced Non—Small-Cell Lung Cancer: A Randomized, Multicenter Phase III Trial(2004)

134 cited

→ Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence(2016)114 cited

→ CD4+CD25+ Regulatory T-Cell Frequency in HER-2/neu(HER)-Positive and HER-Negative Advanced-Stage Breast Cancer Patients(2007)108 cited

→ Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence(2016)107 cited